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Diabetes mellitus remains one of the leading causes of morbidity and mortality worldwide. According to the Centers for Disease
Control and Prevention, approximately 23.6 million people in the United States are aﬀected. Of these individuals, 5 to 10% have
been diagnosed with Type 1 diabetes mellitus (T1DM), an autoimmune disease. Although it often appears in childhood, T1DM
may manifest at any age, leading to signiﬁcant morbidity and decreased quality of life. Since the 1960s, the surgical treatment for
diabetes mellitus has evolved to become a viable alternative to insulin administration, beginning with pancreatic transplantation.
While islet cell transplantation has emerged as another potential alternative, its role in the treatment of T1DM remains to be
solidiﬁed as research continues to establish it as a truly viable alternative for achieving insulin independence. In this paper, the
historical evolution, procurement, current status, beneﬁts, risks, and ongoing research of islet cell transplantation are explored.
1.Introduction
In part one of this two-part paper, pancreas transplantation
was explored as the deﬁnitive treatment for patients with
Type 1 diabetes mellitus (T1DM) [1]. It is estimated that of
the 23.6 million people diagnosed with diabetes mellitus, 5–
10% consist of patients with T1DM [2]. Moreover, recent
reports indicate that the incidence of T1DM is increasing,
with one study predicting an increase of 70% in those under
the age of 15 by 2020 [3–6]. Accordingly, the signiﬁcant pop-
ulation already aﬄicted with this disease compounded by
the increasing incidence worldwide will have a tremendous
impact on future healthcare both domestically and globally
[7]. Estimates show that patients with T1DM treated with
intensive medical management have six- to sevenfold higher
directcostthanage-matchednondiabetics[8].Althoughcost
is a concern, it is the long-term complications of T1DM that
result in the extensive morbidity in this population which
fuel the desire for viable alternative treatments from the
standard of care, intensive insulin therapy [9]. Even with
the mainstay treatment, patients are still at signiﬁcant risk
for complications including retinopathy, neuropathy, neph-
ropathy, coronary artery disease, peripheral vascular disease,
and cerebral vascular disease. While the etiology of this dis-
ease remains elusive, it is believed that a relationship exists
between genetic susceptibility and environmental factors, in-
cluding infections and toxins, which results in its fulminant
presentation [10, 11].
The quest for a surgical treatment for T1DM ﬁrst began
more than a century ago with the likes of Oskar Minkowski
and Josef von Mering at the University of Strasburg, Stras-
burg, Germany [12, 13]. It was not until 1966 when success
was achieved by Kelly et al. who completed the ﬁrst whole-
organ pancreatic transplant at the University of Minnesota
[14].Soonthereafter,theconceptofisletcelltransplantation,
originating with and developed by the visionary Paul Lacy
and longtime research partner David Scharp at Washington
University in St. Louis, would come into its research phases
and be driven further with the likes of John Najarian and
David Sutherland at the University of Minnesota [15–17].
Initially,itwasmetwithtremendousoptimism.However,the
brilliant concept has been troublesome in allowing clinicians
to maximize on the idealized potential that lies within it in
treating patients with T1DM. Even now, the America Dia-
betes Association only endorses islet transplantation not2 Journal of Transplantation
as a therapeutic alternative, but rather as “performed only
within the setting of controlled research studies” [18].
This paper will now focus on islet cell transplantation as
a potentially enhanced alternative therapy for intensive in-
sulin therapy and as a minimally invasive alternative to pan-
creatic transplantation. It will begin with a brief history of
islet cell transplantation, followed by its current state, and
then the procedure’s beneﬁts and risks. It will continue with
a discussion of current research, highlighting barriers and
potential therapies, to reduce islet mass loss following trans-
plantation,andimagingasameanstofollowthehealthofthe
islet mass. It will end with a discussion on islet autotrans-
plantation as it stands today, primarily as an alternative for
the treatment of chronic pancreatitis.
2. Brief History
Initially, the presence of the exocrine portion of the pancreas
proved to be problematic in the transplantation of fragments
of pancreas in animals due to the destructive nature of the
enzymes [19]. However, this problem was circumvented in
1965 when Moskalewski used collagenase to separate intact
islet from a guinea pig’s pancreas [19]. Islet cell transplanta-
tion subsequently was initiated by Ballinger and Lacy and
Reckard et al., who, in 1972, were the ﬁrst to report that iso-
latedisletscouldreversetheeﬀectsofexperimentallyinduced
diabetes [20, 21]. Ballinger and Lacy transplanted 400 to 600
islets obtained from four donor rats intraperitoneally into
their diabetic counterparts following the administration of
streptozotocin (STZ) to induce the diabetes [20]. After islet
cell transplantation, the recipient rats regained their normal
weight, reduced their glycosuria, and achieved normogly-
cemia [20]. A key discovery in islet transplantation was when
Kemp et al. compared graft eﬃcacy as a function of graft
location. They achieved normoglycemia in STZ-induced
diabetic rats through injection of islet cells into the portal
vein but not in rats in which islet cells were transplanted
intraperitoneally [22]. Monkeys, however, proved to be more
challenging. Scharp et al. were only able to partially alleviate
STZ-induced diabetes in monkeys, which was attributed to
aninsuﬃciencyofisletcellsaswellasallograftrejection[23].
Mirkovitch and Campiche made signiﬁcant advances
when they demonstrated that diabetic dogs could achieve
normoglycemia by autotransplantation of pancreatic islet
tissue [24]. Using collagenase to digest the pancreas, the par-
tially puriﬁed islets were injected into the spleen through the
splenic vein [24]. Subsequent splenectomy resulted in a dia-
betic state [24]. Kretschmer et al. demonstrated that direct
injection of the pancreatic tissue into the splenic pulp was
more eﬀective than injection through the splenic vessels and
the portal vein [25]. Mehigan et al. demonstrated the impor-
tance of the size of the minced particles and their inﬂuence
ontheoutcomeofislettransplantationindogs.Theyalsoob-
served poor outcomes in relation to acinar cell atrophy and
ﬁbrosis from long-term ductal ligation [26, 27].
Yet, it was Sutherland et al. in 1974 who began the ﬁrst
human trials to treat diabetes using isolated islets from cada-
veric donors [28]. Ten transplants were performed in seven
diabetic patients, all of whom had received a prior renal
transplant for end-stage diabetic nephropathy. Although a
reduction in the exogenous insulin requirement was observ-
ed, complete freedom from its use was not achieved. Failure
of the grafts could not be attributed to any speciﬁc reason
but rather secondary to a combination of rejection and inad-
equate islet cell mass [28]. In 1980, Largiader et al. became
the ﬁrst to report insulin independence following islet allo-
transplantation in a Type 1 diabetic [29]. The second report
was not made until 1990 by Scharp et al. [30]. Socci et al., in
a study of six islet-cell transplant recipients with T1DM, also
achieved insulin independence in a patient who underwent
islet after kidney transplantation. Six months following islet
transplantation, the patient achieved insulin independence
with normal values of HbA1c, 24-hr metabolic proﬁle, and
oral glucose tolerance test. This was sustained for a ﬁve-
month period [31]. Other subsequent cases were reported
throughout the 1990s from the Universities of Alberta, Min-
nesota, and Pittsburgh [32–34].
Between 1990 and 1995, 180 patients underwent islet cell
transplantation worldwide [35]. Of these, 96 were recorded
in the international islet transplant registry. 53% of the pa-
tients had islet cell function for as long as a week, but graft
survival reduced to 26% after one year. Only 7% became
insulin independent [35]. In 1994, the University of Giessen
introduced protocol changes that signiﬁcantly improved the
eﬃcacy of islet cell transplantation [36]. In all 12 of their
patients,theisletgraftsurvivedformorethan3months,and,
in 9 patients, the graft functioned for at least a year. Four of
these patients attained insulin independence [36, 37]. These
results were conﬁrmed independently with signiﬁcant im-
provement in graft survival and insulin independence [38,
39].
Throughout the 1990s, and even through today, islet cell
transplantation continues to face a number of challenges:
transplantinganadequatemassofislets,theadverseeﬀectsof
the diabetogenic immunosuppression, islet graft loss due to
immunologic rejection, identifying an optimal location for
transplantation, and overcoming the shortage of pancreata
[40–42]. Arguably the most signiﬁcant advancement in islet
transplantation eﬃcacy was made in 2000 by the Edmonton
group, whose attempt to address the shortcomings of
pancreas transplantation allowed for a tremendous improve-
ment in the islet transplantation protocol. They transplanted
an islet mass from two to four donors and avoided glucocor-
ticoids while minimizing the use of calcineurin inhibitors.
This was accomplished through use of sirolimus, low-dose
tacrolimus, and daclizumab. As a result, they were able to
achieve insulin independence in all the seven of their
patients but required the use of 15 donor pancreases to do
so [43]. In their follow-up international trial, 36 patients
with T1DM received 77 islet infusions at nine sites. 16
patients (44%) achieved insulin independence at one year
postﬁnal infusion with 10 patients maintaining partial graft
function and the last ten with complete graft loss. These
results, thus, conﬁrmed the potential long-term viability and
reproducibility of islet cell transplantation, albeit with room
for achieving greater results [44].Journal of Transplantation 3
3. Islet Isolation
Some of the most extensive research in islet transplantation
has involved identifying avenues for improvement in the
steps necessary to isolate an adequate islet cell mass. Follow-
ing the procurement and preservation of the pancreas, islet
cellsundergothefollowingsteps:digestion,puriﬁcation,cul-
ture, assessment, and, lastly, transplantation.
According to CITR, 85% of reported islet transplants
employed either the University of Wisconsin (UW) or two-
layer methods for pancreas preservation [45]. The two-layer
method (TLM), created by Kuroda et al., was developed as
a means to increase oxygenation and protect organs from
hypoxia through the use of perﬂuorocarbon during cold pre-
servation [46, 47]. As a result of the oxygenation, adenosine
triphosphate production is maintained at the perﬂuorocar-
bon and UW interface [47–49].
3.1. Digestion. One of the key advances in islet cell trans-
plantation was the development of the automated method
of pancreatic digestion with the use of the Ricordi Chamber,
based on the work of Moskalewski and Lacy, which was able
to increase islet yield [50–52]. Based on CITR, Liberase HI
was the most commonly implemented collagenase, used for
processing in 77% of cases, followed by Serva Collagenase
NB1, used in 18% of cases [45]. Liberase HI was identiﬁed in
thelate1990sasacollagenasethatdemonstratedsuperioren-
zymatic action over the traditional collagenase preparation
(Type P) [53, 54]. However, concerns were raised regarding
the small potential risk of bovine spongiform encephalopa-
thy when it was revealed that Liberase HI is isolated from
Clostridium histolyticum grown in media containing brain-
heart infusion broth [55]. In Japan, three-year follow-up
studiesofrecipientshaverevealednoincidencesofpriondis-
eases [56].
Concerns still remain; thus, research has been conducted
for viable collagenase alternatives. Recently, Roche Diagnos-
tics has provided the mammalian tissue-free Liberase MTF-
S as an alternative to its Liberase HI [57]. In their study,
Shimoda et al. compared four collagenases: Liberase HI,
Liberase MTF C/T, Serva Collagenase NB1 Premium Grade,
and Clzyme Collagenase HA. They indicated that the three
alternative enzymes would enable for higher islet yields than
with Liberase HI [58]. When comparing Collagenase XI to
Liberase HI, Collagenase XI resulted in a decline in function-
al capacity of islets which was restored during cultivation.
However, Liberase HI exhibited greater functional capacity
during isolation and the subsequent seven days of cultivation
[59]. O’Gorman et al. compared Liberase MTF to the Serva
Collagenase NB1 and observed comparable results bet-ween
the two collagenases [60]. Of note, in a large-scale com-
parison of Liberase HI to Collagenase NB1, Liberase was
observed to be more eﬃcient for pancreas dissociation but
was observed to be more harmful to exocrine cells and islet
tissue [61]. Szot et al. at the University of California, San
Francisco, have also shown success by implementing the
Serva enzyme blend of Collagenase NB1 and Neural Protease
NB using a systematic approach and identifying donor crite-
ria to achieve clinically implementable results [62]. Another
available collagenase, Vitacyte, was compared with Serva
NB1 and not only showed comparable results but exhibited
markedlydecreasedtimerequiredtoreleaseasigniﬁcantislet
number from acinar tissue, thus, potentially allowing for
increased preservation of islet integrity in the future [63].
In summary, a number of enzymatic blends and collage-
nasesareavailable,andmorestudiesarebeingconductednot
onlyastotheireﬃcacybutalsowithregardstocharacterizing
themicrostructurewhichdeﬁnesthepancreastooptimizeits
dissociation. Consequently, continued research is necessary
to identify which product or mixture of components will re-
sult in the greatest islet yield and functionality.
3.2. Puriﬁcation. After enzymatic digestion of the pancreas,
theremainingcontentsthenundergopuriﬁcationtodecrease
transplanted tissue volume, albeit with minimal loss of islet
cells. This step has typically been performed with the cell
processor COBE 2991, which uses the diﬀerences in density
of the islet cells and exocrine tissue to separate them [64–
66]. The gradient media implemented in this step have tradi-
tionally been the Ficoll solution, ﬁrst described by Lake et
al. in the early 1970s, as another means to improve recovery
of islet cells [65]. The process was further advanced by Olack
et al., who used the organ preservation solution Euro-Collins
to dissolve in which the Ficoll powder [47, 67].
According to CITR, all cases of islet transplantation
implemented the use of a density medium [45]. While a
number of density media have been researched, Iodixanol
has recently revealed positive outcomes in islet yield [68, 69].
Noguchi et al. showed a much larger islet yield when using
Iodixanol as compared to Ficoll solutions [68]. This may be
attributed to its ability to reduce cytokine/chemokine pro-
duction, which, as Mita et al. observed, led to a signiﬁcant
reduction in the loss of islet cells during culture [70, 71].
However, this group has observed comparable islet recovery
rates to the Ficoll-based density gradient during density
puriﬁcation [70, 71].
3.3. Culture. As reported to CITR, 54% of islet masses were
cultured, deﬁned as six or more hours in a specially pre-
pared nutrient medium, for a median time of 27 hours
[45]. Generally, the most commonly used culture medium is
the Connaught Medical Research Laboratory-based Miami-
deﬁned media no. 1, which has shown positive outcomes
compared with alternative media [72, 73].
Theuseofculturehasbeensomewhatcontroversialwhen
compared with the use of fresh islets and has actually
shown a reduction of islet mass and functionality [47, 74–
76]. The University of Minnesota recently concluded that,
while it is not disadvantageous with regards to recovery of
islet function, there is increased expression of several stress-
related genes [77]. Nevertheless, culturing islets has some
advantages as it allows for functional assessment of islets,
preservation during travel time, and recipient preparation in
attaining therapeutic levels of immunosuppression [47, 78–
80]. Immunologic advantages have also been observed [81,
82]. Furthermore, it may allow time for quality control and
for modiﬁcations to promote islet survival [47, 80, 83].4 Journal of Transplantation
In a study of 104 islet preparations, Kin et al. identiﬁed
several factors by univariate analysis contributing to islet loss
during culture, including longer cold ischemia time, two-
layer method preservation, lower islet purity, and higher islet
index. By multivariate analysis, they observed higher islet
index and the use of the two-layer method as factors as well.
Islet yield also signiﬁcantly decreased after culture for 20
hours [84].
With regards to modifying the culture to increase islet
yield, few potential supplements have emerged. Because of
the relative impurity of cultured islets, the presence of exo-
crine tissue may be problematic in damaging the islet cells.
Thus, Loganathan et al. recently showed improved islet re-
covery while preventing insulin cleavage with the addition
of α1-antitrypsin (A1AT) to culture, hypothesizing that the
added enzyme may protect insulin from cleavage by protease
activity [85]. Toso et al. described increased yield with the
addition of liraglutide, the long-acting human glucagon-like
peptide 1 analogue [86].
Thetemperatureatwhichisletsareculturedhasalsobeen
a point of controversy. Most groups have based their culture
at a range of 22–24◦C based on the initial work by Lacy et al.
[87]. Noguchi et al. recently observed improved outcomes of
islet transplantation at 4◦C( <5% loss) than that at both
22◦C (19% loss) and 37◦C (24% loss) [80]. Others have also
observed decreased rates of recovery at 37◦C relative to the
l o w e rt e m p e r a t u r e sa sw e l l[ 88, 89].
3.4. Assessment. While the quantiﬁcation of islets remains a
high priority, assessing their functionality prior to transplan-
tation allows for a predictive component to the procedure to
decrease the rate of posttransplant graft failure. The most
widely used method is dithizone staining with manual and
visual counting of islet equivalents under a light microscope,
while viability has been evaluated by assessing mem-
brane integrity with ﬂuorescein diacetate/propidium iodide
(FDA/PI) [90]. These methods currently have disadvantages
which limit their usefulness. Major limitations include the
assessment of three-dimensional islets in two-dimensional
planes, lack of ability to identify irreversibly damaged plasma
membranesthathavenotyetpermeabilized,operatordepen-
dency, its inability to distinguish endocrine (islet) from exo-
crine (contaminant) tissue, and lack of correlation with
mitochondrialfunctionassays,nudemousebioassay,andcli-
nical outcomes [90]. As such, new methods have been and
are currently being developed.
Computer-assisted digital image analysis has been gain-
ing support as a means of providing more accurate, consis-
tent, and reproducible results in quantifying islet cells. This
was recently aﬃrmed by a multicenter study involving all
eight member institutions of the National Institutes of
Health-supported Islet Cell Resources Consortium [91].
Others have validated this ﬁnding as well [92].
Measuring oxygen consumption rate (OCR) and OCR/
DNA have gained attention in their ability to predict islet
graft function and diabetes reversal [93–96] .P a p a se ta l .
applied the measurements in a model for predicting trans-
plant outcome in mice and obtained sensitivity and
speciﬁcity values of 93% and 94%, respectively. The mea-
surements were also found to be valuable in predicting the
marginal mass required for reversing diabetes [97]. Sweet et
al. have demonstrated that the glucose-stimulated changes in
OCR were predictive of diabetes reversal in mice and that the
changes observed were more due to islet cells than nonislet
cells [94, 95].
With regards to viability, Papas et al. compared the ratio
of ATP to DNA with the ratio of ADP to ATP. They discov-
ered that ATP/DNA as a better measure of viability as ATP
levels ﬂuctuate signiﬁcantly and reversibly with metabolic
stress [96]. They also cited the substantial disagreement that
existsastothesigniﬁcanceoftheADP/ATPaswellasareason
for its limited use [98–100].
The University of Wisconsin recently presented a mul-
tiparametric objective approach to assess islet quality based
on mitochondrial membrane potential (MMP), in vitro
glucose-stimulatedinsulinsecretion(GSIS),andATPtoADP
ratio as a marker of reduced oxidative phosphorylation and
achieved an accuracy of more than 86% in predicting in vivo
functional potency [101].
4. CurrentStateandStatistics
Of the 46 islet transplant centers polled in North America by
theCollaborativeIsletTransplantRegistry(CITR)from1999
through2008,32centersperformedatleastoneisletallograft
transplant, with 27 of those centers reporting detailed
information to the registry [45]. From that time period,
the CITR report includes 81% of both human islet allograft
recipients and procedures conducted in North America. It
includes 412 recipients of islet transplants receiving 828 in-
fusions from 905 donors. Of the 412 recipients, 347 (84%)
received islet-alone (IA) infusions while 65 recipients (16%)
had received a kidney transplant prior to receiving islet in-
fusions (IAK: Islet After Kidney). Both mean recipient and
donor age was 44 years, with recipients characterized by
a mean duration of diabetes of 28 years. Mean time from
cross-clamp to pancreas recovery was 44 minutes, while cold
ischemic time was 7.3 hours. Only 11–15% of patients re-
mained insulin-independent throughout the ﬁrst year [45].
Figure 1 illustrates the total number of islet transplant
procedure performed and the number of recipients in the
32 active North American transplant centers [45]. Figures
2 and 3 illustrate possible states after ﬁrst and last infusion
[45]. In 2008, 66 islet allograft procedures were performed,
with 32 patients receiving their ﬁrst allograft. Both are an
increase from 2007, in which 42 procedures were performed
with 20 patients receiving their ﬁrst allograft. However, these
are still only approximately half the number of procedures
performed and patients receiving a ﬁrst allograft compared
to 2005 [45, 102].
By the end of the ﬁrst year following islet infusion, 65%
of IA patients were reinfused. 8–12% of IA recipients retain
detectableC-peptidewhilebeinginsulindependent.Without
reinfusion as a factor, insulin independence in IA recipients
declines to 27% at year 3. Furthermore, from the last infu-
sion, the rate of loss of islet function steadily increases fromJournal of Transplantation 5
0
20
40
60
80
100
120
140
160
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Number of human islet allograft
procedures conducted (total = 783)
Number of patients receiving their
ﬁrst allograft (total = 408)
N
u
m
b
e
r
o
f
a
c
t
i
v
e
i
s
l
e
t
t
r
a
n
s
p
l
a
n
t
p
r
o
g
r
a
m
s
i
n
N
o
r
t
h
A
m
e
r
i
c
a
(
N
=
3
1
)
Figure 1: Total number of islet transplant recipients and total in-
fusions in North America, 1999–2008, based on the CITR 2009 An-
nual Report [45].
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Figure 2: Possible states after ﬁrst infusion.
12% at month 6 to 42% at year 4. The proportion of patients
retaining graft function with exogenous insulin over the
three-year period remains in the range of 19–31%. Similar
to IA recipients, postﬁrst infusion rates for IAK remain near
20%. Postlast infusion rates remain consistently below those
of IA recipients through the four-year period as well. These
trends of increasing graft loss and decreasing insulin inde-
pendence over time following infusion prevail regardless of
the total number of infusions given, although these rates
diﬀer somewhat [45].
If the number of infusions is taken into consideration, a
second- or third-repeat infusion has a more signiﬁcant role
in increasing the proportion of insulin-independent recipi-
ents from the beginning of infusion to the 500-day period
after infusion. Thus, the greater number of infusions a
patient receives, the quicker the recipient will attain insulin
independence. Thereafter, the percentage of insulin-indep-
endent patients declines at a similar rate until the 900 day
mark to the 1100-day mark (3-year mark) regardless of
Infusion 1 Infusion 2 Last
Insulin
independent
Insulin
dependent
Primary non-
function
Islet failure
Loss of insulin
independent
Figure 3: Possible states after last infusion.
the number of infusions. Of the patients who attain insulin
independence, 70% maintain this status after one year, and
45% maintain it at three years. Furthermore, graft function
continues to decrease over time as well, with 35% of all
recipients losing graft function at the three-year period after
their last infusion [45].
At this point, it may be logical to compare the results
of islet cell transplantation that of pancreas transplantation.
However, a true comparison with regards to graft function at
this time cannot be performed due to the far superior results
of pancreas transplantation. Following pancreas transplan-
tation, 1-year posttransplant graft survival remains ∼78–
85% and at 3 years, 60–80%. Patient survival in pancreas
transplantation at 1 year exceeds 95% for all three categories:
Simultaneous Pancreas Kidney (SPK), Pancreas After Kidney
(PAK), and Pancreas Transplant Alone (PTA) [103–105]. 3-
year survival rates exceed 90%. Speight et al. did perform a
review of twelve studies which compared patient-reported
outcomes (PRO) of Pancreas After Kidney (PAK), Pancreas
Transplant Alone (PTA), IAK, and IA transplantations, and
found beneﬁts with regards to fear of hypoglycemia, diabet-
es-speciﬁc quality of life, and general health status. On the
other hand, shortcomings were observed with short-term
pain, immunosuppressant side eﬀects, and depressed mood
associated with loss of graft function. Thus, as they con-
cluded, much has yet to be learned in terms of patient-based
quality-of-life outcomes in comparing the diﬀerent types of
pancreastransplantationwithisletcelltransplantation[106].
Optimistically; however, while there is no standard
tool to eﬀectively monitor islet cell rejection, Toso et al.
monitored the immune reactivity against islet cell grafts in
mice using enzyme-linked immunosorbent spot (ELISPOT)
assay to identify the ex vivo release of γIFN from splenocytes
stimulated by islet donor extracts. They were able to demon-
strate transiently increased levels of immune reactivity, as
indicated by reactivity of splenocytes against islet proteins,
in allogeneic models, and were able to achieve a sensitivity of
70% and speciﬁcity of 94% [107]. In the future, such data,
combined with the gradual improvement in islet eﬃcacy,
may prove to inﬂuence and help guide the patient’s decision
as to the appropriate treatment thereafter.
5. Beneﬁts
Islet cell transplantation has been endorsed as having a
largely beneﬁcial impact by several groups with regards6 Journal of Transplantation
to achieving stronger metabolic control over brittle dia-
betes and reducing the tremendous physiologic impact of
T1DM. Although improvements in the counterregulation
and symptom-recognition mechanisms with respect to
glucagon and epinephrine may be observed, values continue
to be considerably below normal [108–110]. However, this
drawback may be mitigated as growth hormone levels are
restoredandnormalized[107].Furthermore,autonomicand
neuroglucopenic hypoglycemia warning symptoms return
even in individuals with longstanding diabetes [111]. Long-
term beneﬁts of islet graft function include near-normal
HgbA1c levelsandreasonableglucosecontrolwithoccasional
insulinindependence[112].AccordingtoCITR,thepercent-
age of IA recipients with normal HbA1c levels increased from
2%preinfusionto51–60%atyearoneafterlastinfusion[45].
In a study of seven IAK transplant recipients, a near two-
point reduction in HgbA1c was observed with 30% achiev-
ing 1 year insulin independence and 86% with one year
graft function. No severe hypoglycemic events were reported
[113]. In their study, Warnock et al. enrolled 10 patients
with diabetes-induced renal dysfunction in a best medical
therapy program and then crossed them over to islet
transplantation. All patients showed improved metabolic
control reducing HbA1c from a mean of 6.9% after best care
to 6.2% 6 months after islet transplantation [114]. Poggioli
et al. observed signiﬁcant nutritional and dietary changes
in 30 of 52 islet transplant recipients, including substantial
reductions in body weight, body mass index, waist circum-
ference, and fat weight [115]. Considerable progression of
diabetic retinopathy is also much more likely in patients
with intensive insulin therapy as opposed to islet transplant
recipients, in whom it was shown to stabilize [116, 117].
Cardiovascular function improved as well in patients
with end-stage renal disease (ESRD) receiving both kidney
andislettransplantsrelativetopatientsreceivingkidneyonly,
with improvements in atherothrombotic proﬁle and endo-
thelial morphology [118]. The same IAK group also had
improvements in ejection fraction and peak end-diastolic
volume (EDV) and stabilization in time to peak ﬁlling rate.
These indices were diminished in the kidney-only group
[119]. Furthermore, renal graft survival and function were
also improved when combined with islet cell transplantation
[120]. Poor long-term outcomes of polyneuropathy were
also prevented in patients undergoing the IAK procedure, as
evident with a reduction in advanced glycation end products
(AGEs) and expression of their speciﬁc receptors (RAGE)
[121].Leeetal.havealsoshownthatpatientsmaystabilizeor
even demonstrate improvement of their diabetic neuropathy
[117].
6. Risks
In the short term, the risk associated with islet transplanta-
tion is pointedly less, in comparison with whole-organ pan
creatic transplantation. However, similar to pancreas trans-
plantation, longer-term complications are likely associated
with the chronic necessity for immunosuppression and are
highlightedbythewell-knowncalcineurininhibitor-induced
nephrotoxicity, which becomes more important due to the
potential preexistence of diabetic nephropathy [122–125].
The Edmonton Group, in a review of 34 patients under-
going 68 procedures, recorded potentially serious complica-
tions in only 6 of 68 procedures [126]. Complications in-
cluded two patients with portal venous thrombosis and four
patients with clinically signiﬁcant intra-abdominal hemor-
rhage [126]. Bleeding was also observed in 18 of 132 percu-
taneous transhepatic islet transplants in 67 patients by Vil-
liger et al. from 1999 to 2005. However, they did conclude
that the complication is avoidable if the intraparenchymal
livertractissealedeﬀectively[127].Maleuxetal.reportedon
15 patients who underwent 31 procedures. Only three pat-
ients presented with complaints of transient abdominal pain,
which furthered the notion that percutaneous transhepatic
injection of islet cell grafts is a safe and reproducible pro-
cedure [128]. From 1992 through 2003 at the University
of Geneva Hospital in Switzerland, 62 percutaneous tran-
shepatic injections were performed. Nine complications
(14.5%) were observed, of which two were portal vein thro-
mbosis and seven were intra-abdominal hemorrhage [129].
In their study of seven IAK recipients, Cure et al. reported
two procedure-related pleural eﬀusions and one episode of
cholecystitis, all of which resolved [113].
As mentioned above, sensitization is another potential
threat following a failed islet transplant. This was illustrated
by the Edmonton Group in which 16% of the recipients
became sensitized after transplantation, with de novo anti-
bodies seen in 36% of sensitized and 33% of nonsensitized
recipients [130]. In their international trial, they reported
procedural-related complications including acute intraperi-
toneal bleeding in 7 of 77 (9%) with four requiring blood
transfusions and the other requiring laparotomy. No cases of
portal vein thrombosis were reported. Two of the 36 patients
hadpartialportalbranchveinocclusions,buttheyweresucc-
essfully treated with anticoagulation [44].
7. Ongoing Debateand Limitations
Central tothe debatehasbeenwhetherinsulinindependence
should be the main objective in islet cell transplantation
or whether it should simply be to achieve acute and long-
term metabolic control and to improve the quality of life
of individuals with brittle diabetes [131]. At the present
time, support lends itself to the latter. Once again, the inter-
national trial of the Edmonton protocol concluded that,
even with normal endocrine reserves rarely being achieved,
insulin independence is gradually diminished over time.
Considerable metabolic control, however, is achieved with
protection from hypoglycemia and improved HgbA1c levels,
thus, favoring the procedure for highly selected patients after
exhausting all other therapeutic options [44]. Recently, the
GRAGIL group released similar results favoring the use of
islet transplantation as a therapeutic means to achieve stron-
ger metabolic control with respect to restoring beta-cell fun-
ction rather than measuring success by the achievement of
insulin independence [132].
One observed limitation of islet cell transplantation is
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center to center worldwide, which is primarily attributed to
a lack of experience [43]. Another study by the GRAGIL
Consortium proposed a solution to bypass this problem
by being the ﬁrst to employ the Edmonton protocol in a
multicenter setting [133]. They have demonstrated further
feasibility of the multicenter approach by illustrating the
absence of ill eﬀects with regards to shipment of islet cells,
discussed below [134].
To combat the limitations associated with islet cell
transplantation, it may be best to steer the therapy towards
those patients with the most potential for graft survival and
who may beneﬁt the most: high-risk patients with recurrent
episodes of hypoglycemia [135]. Two of the most important
and recurrently identiﬁed aspects regulating islet survival
have been auto- and alloimmunity and the maintenance of
as u ﬃcient islet cell mass. At the Leiden University, it was
shown that the presence and amount of autoimmunity to
one or two antigens determine the survival of islet grafts and,
as such, imply a role in patient selection in the future to
maximize graft eﬃcacy and adjust graft size as needed [136].
Ironically, it has recently been shown that the immunosup-
pression regimen implemented by the Edmonton protocol
may exacerbate this autoimmunity. Monti et al. recently
reported that the protocol may actually be causative in the
long-term failure of islet cell transplantation. Employing
the protocol often results in lymphopenia that is associated
with elevated serum levels of the homeostatic cytokines IL-
7 and IL-15, which expands the autoreactive CD8+ T-cell
population [137].
7.1. Problems with Immunosuppression. As has been docu-
mented, many of the immunosuppressants required in islet
transplantation have also been shown to adversely aﬀect the
transplanted islets. One such familiar consequence of the
use of corticosteroids is hyperglycemia as a result of insulin
resistance occurring from the reduction of insulin-mediated
glucose uptake and utilization [138]. Both Sirolimus and
Tacrolimus inhibit beta-cell regeneration and prevent the
normalization of glucose homeostasis in treating diabetic
mice as well [139]. Tacrolimus has also been observed to
decrease insulin gene transcription, the stability of insulin
mRNA, in vitro insulin synthesis and mitochondrial density,
and in vivo insulin secretion, while Sirolimus decreases in
vitroinsulinsynthesisandsecretion,ductalcellregeneration,
and angiogenesis [140–149]. Additionally, mycophenolate
mofetil is a potent inhibitor of ductal neogenesis and has
been shown to impair glucose-stimulated insulin secretion
[150, 151]. However, Johnson et al. have shown that, to some
extent, these negative eﬀects may be counteracted with the
glucagon-like peptide-1 exenatide. The use of exenatide has
shown positive eﬀects on the islet cell graft in stimulating
insulin secretion and improving graft function, thus, aiding
in glycemic control [151–157].
W h i l eav a r i e t yo fg r o u p sh a v eb e e na b l et oa c h i e v e
insulin independence with single donor islet transplanta-
tions, the protocol for this achievement still varies from
group to group [158]. The University of Minnesota achieved
insulin independence in all the eight of its patients with each
patientreceivingonlyoneisletgraft.Theirprotocolconsisted
of daclizumab, etanercept, and thymoglobulin for induction,
withmycophenolatemofetil,Sirolimus,andeithernoorlow-
dose Tacrolimus. Five of eight patients maintained insulin
independence beyond one year, and, in the three patients
who experienced graft failure, it was preceded by subther-
apeutic Sirolimus exposure without measurable Tacrolimus
trough levels [78]. Improved longer-term outcomes have
been achieved at the University of Minnesota as well. Six
patients underwent one or two islet graft infusions with a
protocol of thymoglobulin for induction along with etaner-
cept, cyclosporine, and everolimus for maintenance for the
ﬁrst year following transplantation. Thereafter, mycopheno-
late mofetil or mycophenolic acid substituted for everolimus.
Fivepatientswereinsulinindependentatoneyear,whilefour
remained so at 3.4 +/− 0.4 years after transplant [159].
At the Emory University, they compared the Edmonton
protocol, highlighted earlier, with a protocol consisting of
daclizumab induction, a 6-month course of Tacrolimus, and
maintenance with efalizumab and mycophenolate mofetil.
While two patients achieved insulin independence in the
Edmonton protocol, all four paitnets with the novel protocol
did so [160]. In another study, Matsumoto et al. compared
two common immunosuppression protocols on six patients:
in the ﬁrst, three patients were placed on dacli-zumab
for induction, with Sirolimus and Tacrolimus for mainte-
nance along with etanercept as an anti-inﬂammatory agent;
while in the other, three patients were not only placed
on thymoglobulin for induction and tacrolimus and myco-
phenolate mofetil for maintenance along with anakinra
(anti-IL-β) and etanercept but also provided islet cells with
iodixanol puriﬁcation. While all patients became insulin in-
dependent, the former protocol required two infusions to do
so [161].
At the University of California, San Francisco, a group of
ten patients with T1DM underwent islet transplantation and
was treated with a protocol of thymoglobulin induction and
maintenance with Sirolimus or mycophenolate and either
belatacept (BELA) or efalizumab (EFA). While EFA is no
longer available for clinical use, all ﬁve patients who received
BELA achieved insulin independence after a single islet graft,
with only one requiring insulin use 305 days following trans-
plantation [162].
With increasing knowledge of the negative eﬀects of cer-
tain immunosuppressants on β-cell function, it is hopeful
that novel protocols will continue to develop, and ones that
have achieved successin smallerpopulations willbe implem-
ented on a larger scale so that standardized protocols may
be established. Thus, one may be optimistic that improved
protocols may lead to stronger results in the near future.
7.2. Inﬂammation, the Immune Response, and Oxidative
Stress. Perhaps the major barrier in islet transplantation is
the inevitable decline of islet graft function over the short
and the long terms. Shortly after intraportal transplantation,
more than 60% of islet cells undergo apoptosis during the
revascularization period [163–165]. During the engraftment
process, which may last up to two weeks, oxygen is received
primarily through passive diﬀusion, thus, creating an envi-
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an important contributor to islet dysfunction with resultant
apoptosis and necrosis [168, 169]. One of many facets of
this hypoxic injury is the role that inducible nitric oxide
synthase(iNOS)-nitricoxide(NO)hasinsignalingapoptosis
[170, 171]. Another is the hypoxia-induced activation of
AMP-activated protein kinase in cytokine-induced apoptosis
[172–174]. Subsequently, increased metabolic demand is
requiredof the remaining islets,whichmaylead to metabolic
exhaustion and dysfunction [175].
Defenses, consisting of the innate and adaptive immune
responses, also contribute to the substantial islet cell loss
[176]. The innate immune system creates an environment
ill suited for the survival of the sensitive islet cells. Con-
versely, the adaptive immune response is better controlled
with current immunosuppressive protocols [176, 177]. Not
surprisingly,cytokinesandlow-gradesystemicinﬂammation
promote islet cell dysfunction and death as well [178–181].
One such cytokine is Tumor Necrosis Factor (TNF)α and
its known toxicity to islet cells [180, 181]. Thus, as noted
above, the implementation of etanercept has been more
widely implemented in recent studies at multiple institutions
with promising results [78, 159, 161]. It is hopeful that
these results will be observed once again in the multicenter
Phase 3 trial implementing the Clinical Islet Transplantation
Protocol 07 currently being conducted by the Clinical Islet
Transplantation Consortium [182]. The inﬂammatory en-
vironment in which islets are placed continue to form a cen-
tral barrier to successful graft survival, and targeting it at
diﬀerent levels may achieve more successful results [177].
A number of studies have shown that an avenue of im-
proving islet viability may lie with the role that Toll-like
receptor (TLR) activation has in mediating early islet graft
failure. As part of innate immunity, it activates pathways
such as NFkB, and, if it is inhibited or even partially
suppressed, it may aid in the grafting process [183–185].
Goldberg et al. have shown that carbon monoxide exposure
to isolated donor islets may in fact provide some protection
by blocking the TLR upregulation that occurs during the
isolation procedure [186]. Following activation of the tran-
scriptionfactorNFkBpathway,thereisupregulationofgenes
mediating inﬂammation and apoptosis, thus, supporting its
role as one of the mechanisms of islet loss as well as its
blockade as a potential therapy [187–192]. An additional
potential target may lie with the high-mobility group box
1 (HMGB1) due to its role in mediating early graft loss by
stimulating hepatic mononuclear cells, upregulating CD40
expression, and enhancing IL-12 production by dendritic
cells [184, 193].
An alternative avenue of immunologic research lies
within the role of chemokines, notably monocyte chemoat-
tractant protein-1 (MCP-1)/CCL2, constitutively expressed
in islet cells and their role in monocyte recruitment, insulitis,
islet engraftment, and graft destruction [194–198]. Ogliari et
al. have shown that higher donor levels of MCP-1/CCL2, as
seen with brain death, lead to decreased graft survival in SPK
recipients, likely further contributing to the posttransplant
inﬂammatory state [199]. Similarly, Saito et al. observed
a high expression of both tissue factor and MCP-1/CCL2
expression in isolated islets resulting from brain death and
ischemic stress in the rodent model, thus, emphasizing a role
for pancreatic management from brain-dead donors [200].
Melzietal.havesuggestedthatstrategiestodecreaserecipient
MCP-1/CCL2 maybemorefruitful[201].Leeetal.indicated
beneﬁcial results in the mouse model when blocking MCP-
1/CCL2 binding to its receptor, CCR2 [202]. Interestingly,
two key mediators in the chemokine’s release are NFkB and
Angiotensin II, which is actively generated in the pancreas,
through their increased expression of MCP-1/CCL2 mRNA
and protein [203, 204].
Correspondingly, a few adjunctive therapies have shown
potential in improving islet survival. A role may exist
for adenosine A(2A) agonists as they improve glucose-
stimulated insulin secretion and inhibit inﬂammatory islet
damage in the peritransplant period [205, 206]. Intensive
insulin and heparin administration have also shown beneﬁt
in the peritransplant period [207]. Heparin’s beneﬁcial
eﬀects likely stem from its favorable impact against the
instant blood-mediated inﬂammatory reaction (IMBIR) [83,
207].
While research continues to illustrate the barriers that
exist in the peritransplant period, several potential thera-
peutic targets have been characterized, with a few therapies
showing beneﬁt. Work still remains in this phase and will
only continue to shed light on the tremendous immunolog-
ical underworks that characterize this crucial time frame of
islet stress.
7.3. Optimal Location. A critical facet of islet cell transplan-
tation remains the optimal site of implantation. As noted
above, Kemp et al. were the ﬁrst to demonstrate success
with intrahepatic transplantation and thus has remained as a
favored site for some time [22]. Glucagon unresponsiveness
to hypoglycemia remains a consideration, as noted earlier,
which is in contrast to that seen in whole-organ pancreatic
transplantation. This is thought to be due to the increased
intrahepatic glucose ﬂux masking systemic hypoglycemia
[208–213]. Liver ischemia and procedure-related complica-
tions, such as hemorrhage and thrombosis, are also concerns
[214–217].
Accordingly, several locations have been considered as
possibilities for the future, including vascular (celiac artery,
spleen, lung), organ (renal subcapsule, pancreas, intramus-
cular, omental pouch, intraperitoneal, subcutaneous), and
immunoprivileged (intracisterna magna, testis, and thymus)
sites [217]. Recently, Kim et al. compared the kidney, liver,
muscle, and omentum as islet transplant sites, evaluating
each based on operative feasibility, implantation eﬃciency
assessed as marginal mass required and mean time to achieve
normoglycemia, and glycemic control in the mouse model
[218]. They observed that the omentum may be an optimum
site in terms of implantation and eﬃciency, albeit with dis-
advantages. Namely, it does not allow repeat transplantation,
and it is not possible in patients with a past laparotomy.
On the other hand, muscle oﬀers ease of operative feasibility
but less vascularity. While the liver resulted in much greater
mortality and delayed graft function, it aﬀorded greater
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results in feasibility, eﬃciency, and glycemic control, but, as
noted, diﬀerences exist with respect to the human kidney, as
the subcapsule allows for less elasticity and aﬀords limited
space [218, 219]. Recently, the femur bone marrow cavity
hasalsobeenintroducedasapotentialsiteoftransplantation
of a bioartiﬁcial pancreas (BAP), as reported by Yang et
al. The BAP was composed of mouse insulinoma cells
encapsulated in agarose gel further enclosed in a calcium
phosphate chamber [220]. The group also evaluated the
possibility of applying the BAP to intramuscular space in
a comparison with the intramedullary cavity but reported
increased eﬀectiveness with the latter [221].
Further research has recently been performed with
regards to an intramuscular transplant site. Directly compar-
ing the intraportal site to muscle (biceps femoris) in rats,
Lund et al. observed twice the necessary IEQ to achieve
normoglycemia in muscle [222]. Others have shown some
feasibility of intramuscular implantation as well, observing
much better oxygenation when compared to the renal
subcapsular site in rats but naturally less oxygenation than
that in native pancreatic islets of nontransplanted controls
[223]. Of note, Christoﬀersson et al. showed the importance
of neutrophils in restoring intraislet perfusion following
transplantation at an intramuscular site [224, 225].
Performed in a variety of ways, several reports have been
published with regards to increasing the vascularization of
islet cells transplanted intramuscularly or subcutaneously.
As will be discussed later, Witkowski et al. achieved excel-
lent results when pretreating intramuscular sites with a
biocompatible angiogenic scaﬀold before transplantation
[226]. Salvay et al. created microporous polymer scaﬀolds
produced from copolymers of lactide and glycolide, which
were then adsorbed with collagen IV, ﬁbronectin, laminin-
332, or serum proteins before being seeded with 125 mouse
islets.Thescaﬀoldswerethenimplantedontotheepididymal
fat pad in mice. The scaﬀold with collagen IV maximally
enhanced graft function promoting graft eﬃcacy [227].
A number of studies have shown the potential clinical
impact adjunctive treatment with VEGF has on increasing
islet graft eﬃcacy and viability [228–232]. Stiegler et al. used
a combination of foam dressing, vacuum-assisted wound
closure, and hyperbaric oxygenation (HBO) in rats, with
results indicating increased vessel ingrowth and vascular
endothelial growth factor (VEGF) levels dependent on
duration of HBO treatment. Perfusion was signiﬁcantly
improved in the experimental group with only a small
amount of apoptosis following transplantation [233]. Sim-
ilarly, islet cells transplanted subcutaneously with adipose
tissue-derived stromal cells (ADSCs), and minced adipose
tissue showed increased vascularization and higher capillary
density than mice implanted with either ADSCs or minced
adipose tissue alone [234]. Ohmura et al. indicated that
ADSCs promote survival and insulin function of the graft
and reduced the islet mass required for reversal of diabetes
[235]. Ito et al. demonstrated improved islet graft function
and promotion of graft revascularization when islet cells
were cotransplanted with bone marrow-derived mesenchy-
mal stem cells in rats [236] .D u p r e ze ta l .w e r ea b l et oc r e a t e
composite cells of mesenchymal stem cells and islet cells, and
theyshowedbeneﬁcialresultswithregardstominimizingthe
immune reaction with blood and suppressing lymphocyte
proliferation [237] .O t h e rg r o u p sh a v eo b s e r v e ds i m i l a r
immunosuppressive results and improvements in vascular-
i z a t i o nw i t hm e s e n c h y m a ls t e mc e l l sa sw e l l[ 238, 239].
In another novel study, Shimoda et al. used an ultra-
sound-mediated gene-transfer method named ultrasound-
targeted microbubble destruction (UTMD) to deliver non-
viral plasmid vectors encoding VEGF into the host liver of
mice. They observed that the VEGF gene promoted islet
revascularization following transplantation and improved
rates of achieving normoglycemia [240]. Similarly, Kherad-
mand et al. created an innovative approach to transplant
isletsthroughacombinationofmechanisms.Theycreatedan
extrahepatic site by transplanting islet-loaded microporous
poly(lactide-co-glycolide) (PLG) scaﬀolds into the epididy-
mal fat pad in mice. Ethylcarbodiimide- (ECDI-) treated
splenocytes were infused as a tolerance induction stra-
tegy. Altogether, they experienced excellent results superior
to intraportal transplanted islets [241]. Vaithilingam et al.
observed increased levels of hypoxia-inducible factor-1α
(HIF-1α) and VEGF expression when transplanting encap-
sulated human islets pretreated with desferrioxamine (DFO)
into the peritoneal cavity of mice [242]. Others have noted
theuseofDFOtostimulateVEGFexpressionandisletvascu-
larization as well [243–245].
While the intrahepatic site is the classic location for islet
transplantation, it is likely that other sites will take over this
role. A number of novel approaches have been discussed,
and, considering the improvements observed with inducing
vascularization, an intramuscular location may prevail as the
leading candidate to replace the liver.
7.4. Shortage of Supply. Another major hindrance to human
islet cell research and transplantation remains the shortage
of pancreata. Potential solutions to increase resources lie in
stem cells and xenotransplantation, both of which are being
extensively researched, and in international islet shipping.
At this point, we will focus on recent studies involving the
shipment of islet cells. Vaithilingam et al. recently demon-
strated success of shipping encapsulated islets from Chicago,
Ill, to Sydney, Australia, achieving a recovery rate of 88%.
Islets were encapsulated with a barium alginate microcapsule
and were isolated for a median total of 11 days before
being transplanted in mice [246]. Similarly, Qi et al. showed
success with long-distance shipping of encapsulated alginate
calcium/barium microbeads, maintaining in vitro and in
vivo islet function [247]. Other groups have established the
improvedsurvivalandfunctionalityofalginate-encapsulated
islets as well [248–250]. Ikemoto et al. have also had some
success, shipping islets from Dallas, Tex, to Fukuoka, Japan.
Islets were packed in either gas-permeable bags or non-
gas-permeable bags. Recovery rate was higher in the gas-
permeable group than the nongas-permeable group: 56.4 ±
10.1% versus 20.5 ± 20.6%, P < 0.01. Purity also decreased
to a greater extent in the nongas-permeable group [251].
Ichii et al. have endorsed the use of gas-permeable bags
as well and have promoted shipments following cultured
islets as opposed to that immediately after isolation [252].10 Journal of Transplantation
Because of the changes in pressure and temperature islets
must endure during shipment, Rozak et al. have suggested
the use of containers equipped with commercially available
TCP Phase 22 phase change material (TCP) and custom-
designed pressure regulated gyroscopic shipping containers
(PRGSC), which illustrated excellent environmental control
by limiting temperature and pressure changes [253].
8. Further Research
Optimistic ﬁndings with regards to genetic manipulation
have been observed, with caspase inhibition showing pro-
mise. Islet cells transduced with an X-linked inhibitor of
the apoptosis protein (XIAP) expressing recombinant ade-
novirus were resistant to apoptosis. By inhibiting caspases 3,
7,and9,thisreducedtherequiredtransplantedisletcellmass
[254–256]. However, a drawback remains the required use of
adenoviral gene therapy.
Expanding on caspase inhibition, Emamaullee et al.
employed a short course of the caspase inhibitor zVAD-FMK
a n dd e m o n s t r a t e de ﬃcacy in enhancing marginal mass post-
transplant grafting. Consequently, this illustrated the extent
of damage caused to the islet implants by ischemia. zVAD-
FMK selectively inhibits caspases 1–10 and 12. With renal
subcapsular islet infusion, 90% of zVAD-FMK-treated mice
became euglycemic with 250 islets versus 27% of the control
animals. With portal infusion, 75% of zVAD-FMK-treated
animalsestablishedeuglycemiawithonly500islets,andallof
the controls remained severely diabetic. No systemic toxicity
was demonstrated [257].
In another study, Emamaullee et al. utilized another
caspase inhibitor, EP1013 (zVD-FMK), which selectively in-
hibits caspases 1, 3, 6, 7, 8, and 9, as opposed to the less
speciﬁc zVAD-FMK. No discernable diﬀerence was observed
between the two caspase inhibitors with islets injected in the
subcapsular space, but there was a signiﬁcant diﬀerence ob-
served with islets transplanted intraportally. Nearly 100% of
the EP1013-treated animals achieved euglycemia with 500
islets, while only 62.5% of zVAD-treated animals, and 0% of
the controls established euglycemia. Once again, no systemic
toxicity was observed [258].
More recently, the group conducted another study to
observe the combined eﬀects of EP1013 with CTLA4-Ig, a
costimulatory blocking agent shown to be an eﬀective im-
munomodulatory agent [259]. Fully major histocompatibili-
ty complex (MHC) mismatched mice underwent islet allo-
transplantation. 40% of mice which were administered
CTLA4-Igaloneresultedinprolongedisletsurvivalofgreater
than 180 days, whereas 91% of mice administered both
EP1013 and CTLA4-Ig showed prolonged survival. Treat-
ment with EP1013 alone did not result in prolongation of
allograft survival. Furthermore, in the study, they showed
that the complimentary eﬀects of both drugs reduced the
frequency of intragraft CD4+ and CD8+ T cells both at short
andlongterms,andreducedthefunctionalalloreactiveTcell
response along with B-cell allosensitization [260]. Thus,
there is reason for optimism that this type of therapy could
dramatically reduce the number of islets required to induce
insulin independence, reduce early immune stimulation
from dying islets, and improve current immunosuppressive
regiments to decrease or rid of the need for nephrotoxic
agents.
At the University of Pittsburgh, growth factors, such as
hepatocyte growth factor (HGF), and signaling molecules,
suchasproteinkinaseB(PKB)/Akt,havealsoshownpromise
[261]. Furthermore, combination gene therapy may have a
roleinposttransplant therapy,asshownbytheco-expression
of VEGF and interleukin-1 receptor antagonist and its res-
ultant success in islet survival [262].
9.Imaging
Central to monitoring the progression of islet cells following
transplantation is the role noninvasive imaging will have in
the future, and, to this end, magnetic resonance imaging
(MRI) is one of the major imaging modalities which may
prove valuable. In 2004, Jir´ ak et al. was the ﬁrst to report
a technique for in vitro labeling of isolated pancreatic
islets with the MR-contrast agent Ferucarbotran, composed
of crystalline iron nanoparticles with superparamagnetic
properties coated by carboxydextran, allowing for increased
hydrophilicity and increased uptake by cells [263, 264]. Fer-
ucarbotran is uptaken by islet cells by means of endocytosis
without subsequent deleterious eﬀects on function [265–
267].Thefeasibilityand safetyof this model, speciﬁcallyiron
labeling, to humans was then demonstrated by Toso et al. in
four patients receiving a total of nine islet transplants [267].
Its safety was further noted by Kim et al. who observed no
deleterious eﬀects on either islet function or gene expression
[268].
The ﬁrst clinical human trial implementing this imaging
modality was performed recently by Saudek et al. in eight
patients with T1DM [269]. No side eﬀects related to the
modality were observed. With regards to eﬃcacy in observ-
ing pancreatic mass on MRI, they noted that the labeling
p e r i o dw a sl e s se ﬀective if islets were incubated with Feru-
carbotran for less than 16 hours. Decrease in visualization
occurred one week following transplantation, thus, correlat-
ing with the oft observed early destruction of islets. This also
corresponds with a previous study in rats [270]. Thereafter,
visualization remained stable for up to 24 weeks. As they
concluded, while the modality allows for precise localization
and quantiﬁcation, an exact correlation between total num-
ber of transplanted islets and hypointense spots (as observed
onMR)shouldnotbeexpectedduetoanumberofsuspected
factorsincluding isletcelldestruction,isletsseedingtogether,
lackofdetectionincounting,andrandomdecreasedcontrast
uptake.
While these studies are in their early phases for clin-
ical application, they represent important steps towards
enhancing the monitoring of islet cell transplantation [269].
Recently, ferumoxide has also been introduced as a labeling
agent. Though it exhibits a similar safety proﬁle to Ferucar-
botran, it exhibited inferior iron uptake by islet cells and
increased hepatic clearance, thus, aﬀording less background
[271–274]. In a distinctive use of the MRI, manganese-
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β-cell mass in both static and dynamic conditions without
manganese-associated toxicity, otherwise characterized by
changes in insulin production. While still in its research
phase of implementation, this may yet serve as another
potentialavenueforfurtherresearchofisletgraftmonitoring
[275].
In addition to MRI, bioluminescent imaging has also
been a source of optimism for its potential use in posttrans-
plant islet monitoring [276–281]. First performed by Lu et
al., the group transduced isolated human and rodent islets
withrecombinantadenovirusorlentivirusvectorsexpressing
a ﬁreﬂy luciferase gene under the control of the nonspeciﬁc
cytomegalovirus promoter. The promoter is not subject to
regulation by blood glucose levels so as to accurately reﬂect
the remaining islet graft mass [276]. Luciferase, when it
reactswithitssubstrate,D-luciferinproducesaphotonemis-
sion that may be detected by a cooled charge-coupled device
(CCD)camera.Followingimplantation, theydiscoveredthat
the CCD signal was proportional to the implanted islet graft
mass and that the lentivirus-engineered islets could be repet-
itively imaged long term after transplantation [276]. In a
follow-upstudy,Chenetal.implementedthebioluminescent
imaging model to determine how a change in functional
isletmasscorrelatedwithmetabolicabnormalitiesduringthe
course of posttransplant rejection. They found that imaging
modality was very sensitive, with bioluminescent signals
observed from as few as 10 islets implanted in a variety of
locations. Intensity stabilization occurred within two weeks
and remained so for as long as 18 months after transplant
[277]. Virostko et al. and Grossman et al. also implemented
the bioluminescence model with transgenic mice expressing
luciferase and obtained similar results, noting that small
changes in recovery of bioluminescence correlated with
major changes in blood glucose control [279–281].
As mentioned earlier, in another novel technique,
Witkowski et al. examined an intramuscular transplantation
site and followed graft progression using positron emis-
sion tomography (PET) imaging with [11C] dihydrotetra-
benazine. The site was pretreated with a biocompatible angi-
ogenic scaﬀold, which was found to signiﬁcantly improve
engraftment versus control models. PET imaging visualized
and quantiﬁed the islet mass and also correlated with the
maintenance of normoglycemia by the islet graft [226].
In conclusion, imaging of islet cell mass has made
signiﬁcant strides in the past few years as novel areas of
research develop all while new ones continue to spring
up. And while such research gives enthusiasm for the
potential to improve the evasive in vivo monitoring of islet
survival and functionality, there is still some work required
to establish a more reproducible and readily universally
applicable modality to have a clinical impact.
10. Autotransplantation for
ChronicPancreatitis
Theconceptofisletautotransplantationfollowingpancreatic
resection as a surgical treatment option in patients with
chronic pancreatitis ﬁrst developed at the University of
Minnesota (UMN) in the 1970s, when Najarian et al.
indicated therapeutic value in its role to relieve the pain in
this patient population [17, 282, 283]. However, the side
eﬀect of diabetes must be taken into consideration when
considering it as an alternative [17]. This has an important
role in considering when to revert to surgery for treatment,
as delaying in patients with chronic pancreatitis may lead to
progressive damage of the pancreas and a subsequent decline
in islet yield [284, 285].
In a recent retrospective study, it was found that up to
80% of patients had reduced or eliminated the need for
narcotics [213]. Pain relief is obtained in most patients,
and health-related quality of life is signiﬁcantly improved
[286–291]. A UMN analysis showed that nearly 95% of
adult patients had less pain following surgery [292]. Insulin
independence is preserved long term in about one-third
of patients, with another third having suﬃcient beta-cell
function so that the resulting diabetes is mild and easily
controlled [287]. While there is a decline in graft function
over time, long-term insulin secretion remains evident and
may protect against long-term diabetic complications [293].
In a case study by Illouz et al., a patient suﬀering from
chronic pancreatitis for more than two years and abnormal
glucose tolerance test underwent pancreatectomy and islet
autotransplantation and remains insulin independent 5
years after transplantation with less than 1,000IEQ/kg body
weight [294]. Interestingly, the same group has shown that
no signiﬁcant correlation exists between the number of
islets transplanted and insulin independence. However, this
may be as a result of diﬀerences in the etiology of chronic
pancreatitis, such as secondary to chronic alcoholism [295].
This was in contrast to the University of Minnesota series
[296]. Altogether, it is clear that islet graft function and
eﬃcacy following autotransplantation are greater, even with
the presence of a lower β-cell mass [296, 297].
This same procedure has also been shown to have success
in the pediatric population [298–300]. At the University
of Minnesota, in 18 patients surveyed under the age of
18 suﬀering from chronic pancreatitis who underwent
pancreatectomy and islet autotransplantation, only 7 were
on narcotics, and 10 were insulin independent at 1 year.
They concluded that the severity of diabetes may be reduced
in three-fourths of patients, with higher graft eﬃcacy in
younger patients [298]. They also have identiﬁed that in the
pediatric population, as in adults, performing the procedure
early in the disease course is best to preserve islet cell mass
andthatpreoperativemeasurementoffastingplasmaglucose
is useful for predicting islet yield [301, 302]. Furthermore,
any surgical procedures prior to pancreatic resection should
be avoided [299, 302].
11. Conclusion
Islet cell transplantation for the treatment of diabetes
mellitus has made remarkable strides in its evolution
towards truly becoming an alternative treatment to intensive
medical therapy and pancreas transplantation. However,
as highlighted in this paper, while barriers are identiﬁed12 Journal of Transplantation
and advancements are made, progress remains until it may
be considered a more eﬃcacious and viable alternative to
those already established. Having identiﬁed several areas
that serve against islet survival in the peritransplant period,
there is reason to remain optimistic that new therapies
and protocols will be implemented and, thus, aid towards
the gradual improvement of islet graft eﬃcacy over the
short and long course. In the end, we can hope that islet
cell transplantation will serve to prevent the debilitating
complications of diabetes mellitus and lead our patients to
healthier lives.
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